The Defeat-NCD Partnership was established in January 2018 to help tackle the most significant global health challenge of the century: premature death, sickness and disability from and the associated social and economic impacts of certain non-communicable diseases (NCDs).
Partnering across sectors
The public–private–people partnership is hosted by the United Nations Office for Project Services (UNOPS) and includes governments, multilateral agencies, civil society, academia, philanthropic foundations and the private sector.
At an official launch event during the UN General Assembly on 24
September, Novo Nordisk announced its financial contribution of 5
million US dollars to the Partnership.
See press release.
Urgent need for action
NCDs are the leading cause of death and disability globally, accounting for 71% of all deaths in 2016.1 An increasing number of these deaths occur in low-resource countries, affecting adults at a younger age.1
Each year, 15 million people between the ages of 30 and 69 die prematurely from an NCD. More than 85% of these premature deaths occur in low- and middle-income countries.1
The Partnership will initially focus on diabetes and hypertension. Both conditions are closely related and contribute significantly to the burden of premature mortality and disability from NCDs.2,3 Subsequently, the Partnership will address other NCDs of major prevalence and impact such as certain cancers and lung conditions.
The Partnership will drive action across four key areas:
Visit the Defeat-NCD Partnership website
1. World Health Organization. Noncommunicable Diseases. Fact sheet. 2018; www.who.int/mediacentre/factsheets/fs355/en/. Accessed 2 July, 2018.
2. Epstein M, Sowers JR. Diabetes mellitus and hypertension. Hypertension. 1992;19(5):403-418.
3. Parving H-H, Hommel E, Mathiesen E, et al. Prevalence of microalbuminuria, arterial hypertension, retinopathy, and neuropathy in patients with insulin dependent diabetes. British medical journal (Clinical research ed). 1988;296(6616):156.